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Abstract: BACKGROUND AND AIMS The treatment options for eosinophilic esophagitis (EoE) patients
include drugs (proton pump inhibitors [PPIs], swallowed topical corticosteroids [STCs]), elimination diets,
and dilation. Given the lack of data, we aimed to assess adult EoE patients’ satisfaction with different
EoE-specific treatment modalities. PATIENTS AND METHODS We evaluated therapy satisfaction
recalled over a 12-month period using the validated Treatment Satisfaction Questionnaire for Medication
that assesses effectiveness, side effects, convenience, and overall satisfaction. The score for each scale
ranges from 0 (dissatisfied) to 100 (satisfied). To evaluate satisfaction with nonpharmacologic therapies,
the questionnaire was modified and debriefed into three focus groups. The final questionnaire was sent
to 147 patients. RESULTS The patient response rate was 74%. In the last 12 months, 24, 75, 19, and
9% were treated with PPIs, STCs, elimination diet, and dilation, respectively. Patients identified the
following considerations as important for therapy choice: effect on symptoms (89%), effect on esophageal
inflammation (76%), side effects (69%), and ease of use (58%). Patients found STCs to be effective (83
points), convenient (83 points), and experienced no side effects when using this therapy. When using
STCs alone (43%), overall patient satisfaction was high (86 points). Patients judged PPIs to be most
convenient (89 points), STCs to be a bit less convenient (83 points), and diet to be most inconvenient
(46 points) of the three therapies examined. CONCLUSIONS Adult EoE patients consider both therapy
effect on symptoms and esophageal inflammation as important criteria when choosing EoE therapy and
appear to be satisfied with STC use.
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Abstract
Background and Aims: The treatment options for eosino-
philic esophagitis (EoE) patients include drugs (proton pump 
inhibitors [PPIs], swallowed topical corticosteroids [STCs]), 
elimination diets, and dilation. Given the lack of data, we 
aimed to assess adult EoE patients’ satisfaction with different 
EoE-specific treatment modalities. Patients and Methods: 
We evaluated therapy satisfaction recalled over a 12-month 
period using the validated Treatment Satisfaction Question-
naire for Medication that assesses effectiveness, side effects, 
convenience, and overall satisfaction. The score for each 
scale ranges from 0 (dissatisfied) to 100 (satisfied). To evalu-
ate satisfaction with nonpharmacologic therapies, the ques-
tionnaire was modified and debriefed into three focus 
groups. The final questionnaire was sent to 147 patients. Re-
sults: The patient response rate was 74%. In the last 12 
months, 24, 75, 19, and 9% were treated with PPIs, STCs, 
elimination diet, and dilation, respectively. Patients identi-
fied the following considerations as important for therapy 
choice: effect on symptoms (89%), effect on esophageal in-
flammation (76%), side effects (69%), and ease of use (58%). 
Patients found STCs to be effective (83 points), convenient 
(83 points), and experienced no side effects when using this 
therapy. When using STCs alone (43%), overall patient satis-
faction was high (86 points). Patients judged PPIs to be most 
convenient (89 points), STCs to be a bit less convenient (83 
points), and diet to be most inconvenient (46 points) of the 
three therapies examined. Conclusions: Adult EoE patients 
consider both therapy effect on symptoms and esophageal 
inflammation as important criteria when choosing EoE ther-
apy and appear to be satisfied with STC use.
© 2019 S. Karger AG, Basel
E. Safroneeva and D. Hafner contributed equally to this work.
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Introduction
Three types of therapies, namely drugs, diets, and dila-
tion, are used to manage adult patients with eosinophilic 
esophagitis (EoE) [1, 2]. In EoE, the drug-based therapy 
with most randomized placebo-controlled trial-generat-
ed evidence of efficacy is swallowed topical corticoste-
roids (STCs) taken in the form of either syrup (budesonide 
diluted in sucralose solution), powder (obtained from 
blisters of fluticasone propionate inhaler discus or bude s- 
onide capsules), or spray (fluticasone propionate oral 
aerosol inhaler) [1]. STCs are currently used mostly off-
label given that a formulation of budesonide developed 
specifically for adult EoE patients was only recently ap-
proved by the European Medicines Agency (in 2017) and 
Swiss regulators (in 2018) [3]. Proton pump inhibitors 
(PPIs) are used in a subset of EoE patients responsive to 
this medication or else in those suffering from concomi-
tant gastroesophageal reflux disease [1]. Six-food (or less) 
elimination diet is a non-drug-based alternative for EoE 
management. Just like STCs, the diet may lead to a reduc-
tion in esophageal inflammation and symptom relief [1]. 
Lastly, dilation of strictures often results in symptom re-
lief that may be long-lasting; however, this measure does 
not affect the inflammatory activity of the disease [1]. 
These therapy options are associated with either a risk of 
side effects, potential long-term sequelae associated with 
uncontrolled inflammation (dilation), or else need for 
long-term avoidance of staple foods such as milk, wheat, 
and eggs (diet). As such, patients’ perception of the effi-
cacy and safety as well as lifestyle preferences may pro-
foundly influence the choice of EoE-specific therapy.
To date, adult patients’ satisfaction with various EoE-
specific therapies has not been systematically assessed. 
The Treatment Satisfaction Questionnaire for Medica-
tion (TSQM) is a validated, general measure of patients’ 
satisfaction with medication [4, 5]. We used the questions 
of the TSQM as well as those specifically developed for the 
purposes of this study to perform a questionnaire-based 
survey. In this prospective survey study, we aimed to eval-
uate the utilization of various EoE-specific therapies, as-
sess adult patients’ satisfaction with the therapies they re-
ceived in the last 12 months, and examine factors that are 
important for patients’ choice of therapy.
Patients and Methods
An overview of the key steps described in this section is shown 
in Figure 1.
Study Population
Between September and November 2016, adult EoE patients 
(≥17 years of age) were recruited in one ambulatory care clinic in 
Switzerland as part of the Swiss Eosinophilic Esophagitis Cohort 
Study [6]. Disease diagnosis was established by the investigators 
according to standardized criteria [1]. Patients with concomitant 
gastroesophageal reflux disease were also included.
Development of the Preliminary Version of the Study 
Questionnaire
We first created the questionnaire querying various demo-
graphic and disease-specific characteristics, utilization of various 
EoE-specific therapies, and patients’ satisfaction with the therapies 
used in the last 12 months.
The initial questionnaire contained the following 10 domains: 
sociodemographic characteristics (8 items), EoE-specific patient 
history (3 items), presence of gastroesophageal reflux (1 item), 
presence of atopic diseases (4 items), 5 items on past and present 
EoE-specific therapy (including PPIs, STCs, systemic corticoste-
roids, diets, and dilation), and factors that are important for pa-
tients’ choice of therapy (2 items). In addition, the questionnaire 
contained validated items (questions) from the TSQM that assess-
es treatment satisfaction with various therapies [4, 5]. Patients 
were asked to think of the satisfaction with various therapies when 
looking back at the 12-months period. The TSQM was previously 
translated into German and underwent cultural adaption for Swit-
zerland (TSQM version 1). The validated TSQM covers the most 
relevant aspects of patients’ satisfaction with medication. The 
TSQM consists of 14 items falling into 4 scales: effectiveness (3 
items), side effects (5 items), convenience (3 items), and overall 
satisfaction (3 items) (online suppl. Table 1; for all online suppl. 
material, see www.karger.com/doi/10.1159/000504846) [4, 5]. Un-
like many other similar measures, the TSQM may also be used to 
compare various patient conditions and medication types. The 
TSQM scale was used five times in the initial questionnaire (in-
cluding PPIs, STCs, systemic corticosteroids, diet, and dilation). 
The TSQM scale scores range from 0 (lack of effectiveness) to 100 
(excellent effectiveness).
Focus Groups and Individual Patient Interviews
The focus group and individual patient interviews were con-
ducted in accordance with the ISPOR PRO Good Research Prac-
tices Task Force report [7, 8]. The purpose of the focus groups was 
to aid in the item generation phase of questionnaire development 
and to ensure that “respondents understand how to complete the 
questionnaire, how to reference the correct recall period, the 
meaning of the items, how to use the response scales, and any oth-
er questionnaire features that may influence patient responses in 
the intended mode of administration” [7, 8].
We created semistructured interview guides which contained 
questions and probing strategies to assess patients’ understand-
ing of instructions, stem, response options, and format of indi-
vidual items. Depending on the item, questions/probing strate-
gies were also used to assess appropriateness of recall period. 
Lastly, content coverage, format, and length of the entire ques-
tionnaire were assessed. A board-certified psychologist from the 
Division of Psychiatry, University Hospital Basel, conducted two 
rounds of the cognitive interviews based on these semistructured 
interview guides. Each focus group lasted approximately 2 h. Two 
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 Reviewing of literature
 Gather inputs from EoE and
instrument developing experts
 Adapt TSQM for EoE-specific therapy
 Preparations: patient recruitment,
semistructured interview guide
 Perform focus group
 Create transcription and cognitive
summary report
 Preparations: adapt instrument, patient
recruitment, semistructured interview guide
 Perform focus group
 Create transcription and cognitive
summary report
 Preparations: adapt instrument, patient
recruitment, semistructured interview guide
 Perform interview
 Create transcription and cognitive
summary report
 Create database in EpiData
 Data entry
Fig. 1. An overview of the key steps de-
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(D.H. and either A.M.S. or A.S.). D.H. conducted four individu-
al face-to-face semistructured interviews to find out whether last 
changes to the questionnaire had to be made. An individual pa-
tient interview lasted approximately 40 min. Focus group/indi-
vidual patient interviews were recorded, translated from Swiss 
German (not a written language) into German, and transcribed. 
The research team reviewed the transcriptions of the focus 
groups.
Forty-five and 6 EoE patients were approached during a rou-
tine clinical visit in the EoE clinic (Olten, Switzerland) and invited 
to participate in the focus groups and the face-to-face patient in-
terviews, respectively. Thirty-three and 2 patients declined the in-
vitation for the focus group and the face-to-face patient interviews, 
respectively. Twelve EoE patients were interviewed during two fo-
cus groups (n = 6 for each focus group). Of the 6 patients with a 
mean age of 38.5 years (range 26–51) participating in focus group 
1, 2 were female. Of the 6 patients with a mean age of 47.3 years 
(range 34–63) participating in focus group 2, 1 was female. Four 
male patients with a mean age of 59.5 years (range 44–86) were 
interviewed individually.
Table 1. Characteristics of the respondents
Characteristics (n = 108) Frequency %
Age at EoE diagnosis, years 39.0±15.6 NA
Age at inclusion, years 46.9±15.3 NA
Diagnostic delay, years 2.3 (0.3–9.3), 0–38.3 NA
Disease duration, years 7.6±5.1 NA
Symptom severity as assessed by the EEsAI PRO score1 12 (0–27), 0–65 NA
EoE-specific quality of life as assessed by the EoE-QoL-A2 0.5 (0.29–0.96), 0–1.83 NA
Male sex 85 78.7




ISCED 2011 education level
Level 3 50 46.3
Level 6 or higher 58 53.7
Experienced food bolus impaction requiring endoscopic disimpaction (ever) 39 36.1
Gastroesophageal reflux disease
Ever diagnosed 28 25.9
Heartburn in the last 7 days 29 26.9
Concomitant allergies (ever in life)
Asthma 37 34.3
Allergic rhinitis 64 59.3
Neurodermitis 27 25.0
Known food allergies 42 38.9
More than one condition 54 50.0
EoE-specific therapy
STCs (budesonide or fluticasone), ever 106 98.1
STCs at inclusion 81 75.0
Elimination diets, ever 27 25.0
Elimination diets at inclusion 20 18.5
Esophageal dilation, ever 38 35.2
Esophageal dilation within the last 12 months 10 9.3
PPI therapy
Ever 49 45.4
At inclusion 26 24.1
Values are presented as mean ± SD, median (IQR) and range, or n. EEsAI PRO, Eosinophilic Esophagitis Activity Index Patient-
Reported Outcomes; EoE, eosinophilic esophagitis; EoE-QoL-A, Eosinophilic Esophagitis Quality of Life Questionnaire for Adults; 
ISCED, International Standard Classification of Education [11]; NA, not applicable; PPI, proton pump inhibitor; STCs, swallowed top-
ical corticosteroids. 1 The EEsAI PRO questionnaire assesses symptom severity in adults with EoE; the score ranges from 0 points (no 
symptoms) to 100 points (most severe symptoms) (7-day recall period) [9]. 2 The EoE-QoL-A questionnaire measures EoE-specific 
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Final Questionnaire
We created a cognitive summary report and an item tracking 
matrix documenting all the changes that were made, which in-
cluded the following: (1) a single item assessing the presence of 
atopic diseases was separated into 5 items; (2) the part about treat-
ment satisfaction with STCs was expanded to include three differ-
ent forms of application, namely syrup, powder, and spray, as one 
participant of the focus group took the STC in two different for-
mulations and was satisfied with one form of application, but not 
with another; and (3) several items querying the use of concomi-
tant therapies were introduced.
The final questionnaire (online suppl. material) consisted of 
the following 11 domains: sociodemographic characteristics (7 
items), EoE-specific patient history (3 items), presence of reflux (1 
item), presence of atopic diseases (4 items), concomitant therapies 
(including antacids, H2 receptor antagonists, PPIs, and corticoste-
roids, 7 items), 5 items on past and present EoE-specific therapy 
(including PPIs, STCs, systemic corticosteroids, diets, and dila-
tion), and factors that are important for patients’ choice of therapy 
(2 items). The final questionnaire contained the TSQM, which was 
used six times for assessment of satisfaction with PPIs, STCs (once 
per different application form – syrup, powder, and spray), and 
dilation [4, 5]. The final questionnaire also included the items of 
the Eosinophilic Esophagitis Activity Index Patient-Reported Out-
comes questionnaire and the Eosinophilic Esophagitis Quality of 
Life Questionnaire for Adults [9, 10].
Changes to the TSQM
The TSQM was developed for pharmacologic treatments and 
used in its original form for PPIs and STCs. Given the fact that 
some patients took PPIs and/or STCs for many years, the “I don’t 
remember” response option to item three of the TSQM (“time un-
til the drug started working”) was introduced. The TSQM was 
adapted for diet and dilation, for which not all TSQM items were 
applicable (for diet, the item on ease of use related to formulation 
was removed; for dilation, the entire convenience scale was re-
moved). The word “medication” was replaced with either “diet” or 
“dilation” and a complementary verb.
Data Handling and Statistical Analysis
We double entered the data into the EpiData (version 3.1, Den-
mark) database, compared our entries, and extracted the data into 
Stata (version 13, USA). Data were fairly complete as only two 
missing responses were found for the lead in items that inquired 
whether the patient had taken STCs in the last 12 months, and no 
missing values were found for PPIs, diets, or dilation. For all ther-
apy types, no values for any of the TSQM items were missing. De-
scriptive results are presented as frequencies and percentages of 
the group total or median, IQR, and range. Multivariable logistic 
regression modeling was performed to evaluate the potential fac-
tors that might be associated with the outcome “assigning most 
importance to effects of therapy on symptoms and esophageal in-
flammation as opposed to symptoms alone.” The following vari-
ables were entered into the model as independent variables: age, 
female sex, disease duration, history of esophageal dilation, his-
tory of endoscopic disimpaction, education level (university edu-
cation or equivalent [11]), and anti-inflammatory therapy at the 
time of study participation (either individually or more than one 
therapy). In a first step, the potential associated factors were tested 
separately. In a second step, all factors with a p value < 0.15 were 
entered together into the multivariable logistic regression model. 
To assess the possibility of effect modification, we evaluated pair-




The final version of the questionnaire was sent by mail 
to 147 adults with EoE. The survey response rate was 74% 
(108/147). Patient and disease characteristics are shown 
in Table 1. Mean patient age was 46.9 ± 5.3 years, 85/108 
patients (79%) were male, and mean disease duration was 
7.6 ± 5.1 years. At inclusion, 45, 75, and 19% were treated 
with PPIs, STCs, and food elimination diet, respectively. 
In the past 12 months, 10 patients underwent esophageal 
dilation. Thirty-five patients (32%) were managed with 
more than one therapy (28 patients [26%] with more than 
one anti-inflammatory therapy). Ten patients (9.3%) did 
not receive any treatment.
Table 2. Median TSQM scores and interquartile range
TSQM scales PPI (n = 27); median treatment 
duration 6 years (3–9)
STC (n = 83); median treatment 
duration 5 years (2–6)
Diet (n = 21); median treatment 
duration 2 years (1–4.5)
Effectiveness 66.7 (38.9–77.8) 83.3 (66.7–100.0) 77.8 (50.0–88.9)
Side effects1 100.0 (100.0–100.0) 100.0 (100.0–100.0) 100.0 (100–100.0)
Convenience 88.9 (77.8–100.0) 83.3 (66.7–100.0) 45.8 (33.3–66.7)
Overall satisfaction 71.4 (50.0–85.7) 78.6 (64.3–92.9) 78.6 (50.0–92.9)
Average score 79.9 (70.3–85.5) 84.8 (73.0–93.1) 76.6 (59.8–81.9)
PPI, proton pump inhibitor; STC, swallowed topical corticosteroid; TSQM, Treatment Satisfaction Questionnaire for Medication. 
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Satisfaction with Therapy
The TSQM scale scores as well as the average TSQM 
values for PPIs, STCs, and diet are shown in Table 2 (pa-
tients could be on more than one therapy in the past 12 
months). When judging the convenience of using these 
EoE-specific therapies, patients found PPI use to be most 
convenient (score of 89). Although most patients needed 
to extract the steroid powder-containing blister from the 
discus of asthma-specific medication, they found STCs to 
be relatively convenient (score of 83). Patients on elimi-
nation diet found this therapy to be fairly inconvenient 
(score of 46). Patients did not observe any side effects as-
sociated with the use of various EoE-specific therapies, 
which is consistent with their long-term use (especially 
PPIs and STCs, which were used for the duration of 6 and 
5 years, respectively).
We also examined therapy satisfaction in the popula-
tion that used STCs only (in powder form), STCs togeth-
er with PPIs, and STCs together with elimination diets 
(Table 3). Patients found STCs to be effective (score of 
83), relatively convenient (score of 78), and experienced 
no side effects when using this therapy. When using STCs 
alone, overall satisfaction was fairly high (score of 86).
Criteria Important for the Choice of Therapy
The criteria that patients find important for the choice 
of therapy are shown in Table 4. The effect of therapy on 
symptoms (89%) and esophageal inflammation (76%), 
possible side effects (69%), and ease of therapy use (58%) 
were identified by patients as important considerations 
for the choice of therapy. When asked about the most im-
portant criterion for the choice of therapy (Fig. 2), 45, 32, 
and 11% of patients chose the effect of treatment on 
symptoms and esophageal inflammation, the effect of 
treatment on the symptoms alone, and the effect of treat-
ment on esophageal inflammation alone, respectively, as 
the deciding factor.
Stepwise logistic regression modeling was performed 
to identify factors associated with assigning most impor-
tance to improvement in symptoms and inflammation 
compared to that in symptoms alone as criteria for the 
choice of therapy (Table 5). In the univariable model, fe-
male sex, STC use, and PPI use at the time of the study 
were positively associated with putting greater emphasis 
on improvement in symptoms and esophageal inflamma-
tion compared to that in symptoms alone, whereas pres-
ence of at least a university degree (or equivalent) was 
negatively associated with this outcome. In the multivari-
able analysis, female sex (OR 3.727, 95% CI 0.996–13.944, 
p = 0.050), STC use at the time of the study (OR 3.760, 
95% CI 1.125–12.565, p = 0.031), and PPI use at the time 
of the study (OR 2.911, 95% CI 0.869–9.754, p = 0.083) 
were positively associated with outcome. In the multi-
Table 3. Median TSQM scores and interquartile ranges for STCs in powder form in patients with that therapy only as well as combined 
with either PPIs or diets
TSQM scales STC only (n = 44) STC + PPI (n = 19) STC + diet (n = 9)
Effectiveness 83.3 (72.2–100.0) 77.8 (61.1–94.4) 83.3 (72.2–88.9)
Side effects1 100.0 (100.0–100.0) 100.0 (87.5–100.0) 100.0 (100.0–100.0)
Convenience 77.8 (66.7–100.0) 83.3 (66.7–100.0) 94.4 (83.3–100.0)
Overall satisfaction 85.7 (64.3–92.9) 85.7 (57.1–96.4) 78.6 (71.4–85.7)
PPI, proton pump inhibitor; STC, swallowed topical corticosteroid; TSQM, Treatment Satisfaction Questionnaire for Medication. 
1 On the side effect scale, a score of 100 is given to patients who do not experience any side effects.
Table 4. Criteria important for the choice of therapy (n = 108)
Frequency %
Effect on symptoms 96 88.9
Effect on inflammation in the esophagus 82 75.9
Potential side effects 75 69.4
Ease of use 63 58.3
Treating physician’s recommendation 54 50.0
Compatibility with lifestyle 50 46.3
Price 21 19.4
Recommendation of other patients with 
this condition
12 11.1
One’s own research (for example, on the
internet)
9 8.3
Needs of the family 5 4.6
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variable analysis, we observed a trend for negative asso-
ciation between presence of at least a university degree (or 
equivalent) and outcome (OR 0.406, 95% CI 0.148–1.117, 
p = 0.081). We also carried out regression modeling, in 
which the use of more than one anti-inflammatory ther-
apy at the time of the study (as opposed to each therapy 
individually) was examined. We found that use of more 
than one anti-inflammatory therapy was positively asso-
ciated with putting greater emphasis on improvement in 
symptoms and esophageal inflammation compared to 
that in symptoms alone in both univariable (OR 6.544, 
95% CI 1.753–24.427, p = 0.005) and multivariable analy-
ses (OR 9.294, 95% CI 2.309–37.405, p = 0.002 for more 
than one anti-inflammatory therapy; OR 3.874, 95% CI 
1.061–14.152, p = 0.040 for female sex; OR 0.385, 95% CI 
0.137–1.080, p = 0.070 for presence of at least a university 
degree).
Discussion
This is the first study examining adult EoE patients’ 
satisfaction with different therapies using a validated 
questionnaire. We developed a survey to assess treatment 
satisfaction with EoE-specific therapy by consulting the 
ISPOR guidelines and the literature describing the use of 
the TSQM as well as obtaining input from EoE patients 
by the means of focus groups and individual interviews. 
Table 5. Uni- and multivariable logistic regression evaluating factors associated with assigning most importance to control of inflam-
mation and symptoms (n = 49) over control of symptoms alone (n = 34)
Univariable Multivariable
OR 95% CI p value OR 95% CI p value
Age, years 0.996 0.967–1.025 0.793
Female sex 3.636 1.093–12.098 0.035 3.727 0.996–13.944 0.050
Disease duration (diagnosed), years 1.042 0.949–1.144 0.389
Dilation (ever) 0.922 0.360–2.363 0.866
Disimpaction (ever) 0.809 0.319–2.049 0.655
Education level (ISCED level ≤3 vs. ≥6) 0.390 0.156–0.971 0.043 0.406 0.148–1.117 0.081
STC use at the time of the study 2.451 0.863–6.963 0.092 3.760 1.125–12.565 0.031
PPI use at the time of the study 2.320 0.747–7.207 0.146 2.911 0.869–9.754 0.083
Elimination diet at the time of the study 0.989 0.335–2.922 0.984
ISCED, International Standard Classification of Education; PPI, proton pump inhibitor; STC, swallowed topical corticosteroid.
■ Effect on symptoms
■ Effect on inflammation
■ Effect on symptoms and inflammation
■ Possible side effects
■ Physician’s recommendation






Fig. 2. The most important criteria for 
the choice of therapy. EoE, eosinophilic 
esophagitis; TSQM, Treatment Satisfac- 
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Patients with a long-established EoE diagnosis appear to 
be satisfied with anti-inflammatory therapies, especially 
STCs. We also found that the effects of therapy on symp-
toms and esophageal inflammation were important con-
siderations for the choice of therapy in adults with EoE, 
and that female patients and those using anti-inflamma-
tory therapies at the time of the study were more likely to 
assign greater importance to the effect of therapy on both 
inflammation and symptoms as opposed to symptoms 
alone.
With an average TSQM score of 80, 85, and 77 for 
PPIs, STCs, and diet, respectively, EoE patients appeared 
to be satisfied with these EoE-specific therapies. The 
overall satisfaction scores as well as the various TSQM 
scale scores were consistent with our current knowledge 
about these therapies. It is well known that whilst STCs 
and diets appear to be efficacious/effective in the entire 
EoE patient population, PPIs are only effective in a subset 
of EoE [12]. Hence, the effectiveness scores are higher for 
both STCs and diet when compared to PPIs. Although 
high side effect scale scores are indicative of lack of ther-
apy-related side effects, it is more likely that these patients 
had been diagnosed with EoE for a relatively long time 
and would have had time to switch therapy in case of side 
effects. It is also not surprising that PPIs that are admin-
istered in tablet form received the highest convenience 
score when compared to STC blisters that need to be ex-
tracted from the fluticasone discus inhaler developed for 
asthma patients and diets adhering to which require 
patients to cook their own meals. Given that many of 
the patients take the pharmacologic therapies for an ex-
tended period of time (median treatment duration of 
≥5 years), it is only fitting that overall relatively high sat-
isfaction scores are observed, as both PPIs, STCs, and di-
ets have proven efficacy/effectiveness in patients with 
esophageal eosinophilia [12–14]. The overall satisfaction 
scores might have been different (and potentially lower) 
if therapy satisfaction had been evaluated in newly diag-
nosed patients needing to decide on the type of therapy 
that would work best for them and encountering side ef-
fects of these therapies.
When asked about considerations that are important 
for therapy choice, adult EoE patients consider the effect 
of medication on both symptoms and esophageal inflam-
mation as important. The finding that from the patients’ 
perspective therapy should target both inflammation and 
symptoms is consistent with the choice of endpoints for 
most recent trials testing the short-term efficacy of STCs 
in adults with EoE for the purposes of regulatory approv-
al [15]. We found that female patients and those using 
single anti-inflammatory therapy or a combination of 
those therapies at the time of the study were more likely 
to assign importance to the effect of therapy on both 
symptoms and esophageal inflammation as opposed to 
symptoms alone. Given that the majority of patients re-
ceived a maintenance therapy of 0.25 mg of STC b.i.d., a 
dose that brings only 16% of all patients into complete 
remission, it is likely that disease activity in some of these 
patients on combination therapy was not adequately con-
trolled [16, 17].
According to Atkinson et al. [4], therapy satisfaction 
is a subset of overall patient satisfaction. Besides therapy 
satisfaction, overall patient satisfaction covers all other 
“aspects of medical treatments, interpersonal aspects of 
clinical care, and processes of treatment” [4]. Overall 
patient satisfaction interacts with the behavior of pa-
tients as well as with decision-making. This relationship 
between overall patient satisfaction and patient’s behav-
ior is not considered to be strictly causal in nature, but 
rather an interaction between the domains that can in-
fluence each other. For example, overall patient satisfac-
tion (and therapy satisfaction) can influence patients’ 
behavior. We hypothesize that when an EoE patient is 
satisfied with STC therapy (e.g., because of relative ease 
of use, effectiveness, or few side effects), it is more like-
ly that this patient will pursue the treatment in the long 
run, even though most EoE symptoms will be gone fol-
lowing a short induction treatment. Given that EoE is a 
chronic disease, it is important for patients to adhere to 
anti-inflammatory treatment, as patients with adequate 
disease control have fewer long-term complications 
such as food bolus impactions [18]. It is also possible for 
patients’ behavior to influence therapy satisfaction. We 
hypothesize that an EoE patient who is well informed 
about the advantages (e.g., no need for medication) and 
disadvantages (e.g., may lead to lifestyle alterations) of 
dietary therapy for disease management is more like- 
ly to continue the therapy. As such, one could argue 
that minimizing the rates of therapy discontinuation 
through, among other things, better patient education 
might lead to a higher degree of satisfaction with EoE-
specific therapy.
The results of this study should be interpreted with 
several considerations in mind. Although this is the first 
study attempting to assess patients’ satisfaction with 
various EoE-specific therapies, patients with a long-es-
tablished diagnosis from one gastroenterology practice 
specialized in the management of this condition were 
recruited. It is likely that the high rates of therapy satis-
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ended up with a population of patients that used the 
therapies for a long time; and (2) it is likely that at least 
a proportion of patients, especially those participating in 
various clinical studies, were well informed about the 
various aspects of this disease. As such, our results may 
not be generalizable to newly diagnosed patients or 
those attending less specialized gastroenterology prac-
tices. Whilst patients’ satisfaction with PPIs and STCs 
could be evaluated using the original form of the ques-
tionnaire, the questionnaire had to be adapted for diet 
and dilation. Although minor word changes were per-
formed or else nonapplicable items were removed en-
tirely, satisfaction with diet was queried using a unvali-
dated form of this questionnaire, and the data obtained 
should be interpreted with caution. Although we used a 
validated TSQM, it is important to point out that the 
validity of the overall questionnaire was not rigorously 
assessed. This is especially true for the items querying 
the importance of the effects of therapy on various as-
pects of the disease, as these were not evaluated against 
another valid questionnaire or construct. The rate of di-
etary treatment observed in this study was lower (19%) 
than that observed in centers specialized in elimination 
diets (up to 57% in a mixed adult and pediatric popula-
tion) [19]. However, it is important to point out that re-
moval of inflammation-causing foods, such as milk- and 
wheat-based products, might pose challenges as these 
foods represent important dietary staples of Swiss Ger-
man patients. Therefore, it is likely that, among other 
things, Swiss German patients’ dietary and physicians’ 
personal preferences contributed to high rates of STC 
use in the current population.
In conclusion, we found that patients with a long-es-
tablished EoE diagnosis appear to be satisfied with anti-
inflammatory therapies, especially STCs, and consider 
both symptoms and esophageal inflammation as impor-
tant targets for therapy.
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